Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence of prostate cancer throughout China. The drug-treatment rate has increased over the last few years owing to strong uptake of novel premium-priced therapies and these drugs' inclusion in the NRDL in the 2017 update, especially abiraterone (Janssen’s Zytga). Most recent drug approvals in China (e.g., enzalutamide [Astella’s Xtandi], apalutamide [Janssen’s Erleada], degarelix [Ferring Pharma’s Firmagon] underscore manufacturers' focus on the prostate cancer therapy market in China. Multilabel expansions of marketed drugs to new patient populations are expected.
- How large is China’s drug-treatable prostate cancer population, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs in China’s prostate cancer market and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
- What are the market access considerations for key therapies in the prostate cancer pipeline in China? What sales/uptake could these agents secure in prostate cancer? What are interviewed experts’ opinions of these therapies?
- What are the key drivers and constraints in the Chinese prostate cancer therapy market, and how will the market evolve over the forecast period?
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with medical oncologists and urologists. Supported by survey data collected for this and other DRG research.
Diagnosed incidence of prostate cancer in urban versus rural China; clinically relevant and market-relevant, drug-treatable populations.
10-year, annualized, drug-level sales and patient shares of key prostate cancer agents through 2029, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: 10+ drugs; Phase II: 1 drug
- Prostate Cancer - Geographic Focus: China - Prostate Cancer - China In-Depth (China)
- Prostate Cancer - China In-Depth (China)
Author(s): Karan Verma, MSc; Narendra Parihar
Karan is a Senior Analyst with the China-in-Depth team at Decision Resources Group, where he specializes in disease landscape and forecast reports based on a range of indications and therapy areas and focused specifically on the China healthcare market.
Before joining DRG, Karan was associated with Aranca, a boutique management consulting firm. Prior to that, he was working with Frost & Sullivan, a global healthcare consulting firm, where he was helping clients devise market entry strategies, conducting technology feasibility studies, and doing competitive intelligence for new product development. His prior experience also includes a short KTP program with the University of Southampton, UK. Karan has earned his MSc in Biomedical Engineering from the University of Warwick, and B.E. in Biomedical Engineering from Maharshi Dayanand University, Haryana, India.
Narendra is an associate epidemiologist within the epidemiology team at Decision Resources Group. Narendra specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio.
His qualifications include an MPH with specialization in Health Policy, Economics and Finance from the Tata Institute of Social Sciences, Mumbai, and a Bachelor’s degree in Dentistry from the Rajasthan University of Health Sciences.